CHENGDU, China, July 22, 2011 /PRNewswire-Asia-FirstCall/ —
Tianyin Pharmaceutical Co., Inc. (NYSE Amex:
TPI), a pharmaceutical company that specializes in the
research, development and sale of patented biopharmaceutical
medicine, modernized traditional Chinese medicine, branded generics
and active pharmaceutical ingredients (API) today announced that
the Company has shipped the first batch of Azithromycin API sample
to RELATIONS International Ltd. for Bangladesh export standard
test.
This is the first step for the development of macrolide
international export business for TPI following the signing of the
sales and marketing agreement with RELATIONS International Ltd., a
Bangladesh corporation that specializes in API product sales in the
People’s Republic of Bangladesh, in June this year.
Jiangchuan Macrolide facility (JCM) currently has an active
production license for manufacturing Azithromycin API (H10970072).
Additional information regarding JCM can be found at www.sfda.gov.cn (Chinese
version).
About TPI
Headquartered at Chengdu, China, TPI is a pharmaceutical company
that specializes in the development, manufacturing, marketing and
sales of patented biopharmaceutical, modernized traditional Chinese
medicines, branded generics and active pharmaceutical ingredients
(API). TPI currently manufactures a comprehensive portfolio of 58
products, 24 of which are listed in the highly selective national
medicine reimbursement list, 7 are included in the essential drug
list of China. TPI’s pipeline targets various high incidence
healthcare indications. TPI has an extensive nationwide
distribution network with a sales force of 730 sales
representatives out of totaled 1,365 employees.
For more information about TPI, please visit: http://www.tianyinpharma.com
‘/>”/>
